tradingkey.logo
搜尋

ADMA Biologics Inc

ADMA
添加自選
8.610USD
+0.240+2.87%
收盤 07/01, 16:00美東報價延遲15分鐘
2.00B總市值
12.38本益比TTM

ADMA Biologics Inc

8.610
+0.240+2.87%
查看詳細走勢圖
TradingKey 图表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+2.87%

5天

-1.03%

1月

+8.99%

6月

-52.80%

今年開始到現在

-52.80%

1年

-51.85%

關鍵數據
8.560今開
8.755最高
3.04M成交量
12.38本益比TTM
7.92本益比動
--股利TTM
1.31%換手率
8.370昨收
8.520最低
19.13M成交額
10.12本益比靜
5.12市淨率
0.00%股息率 TTM
28.13%ROA
22.37052週最高
0.77量比
197.67M淨利潤
232.29M總股本
0.6954每股盈餘TTM
0.74Beta
43.30%ROE
7.21052週最低
2.81%振幅
70.48%毛利率
2.00B總市值
3.27回報/風險
3.09%風險率

TradingKey ADMA Biologics Inc股票評分

單位: USD 更新時間: 2026-07-01

操作建議

ADMA Biologics Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在藥品行業排名35/157位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為17.60。中期看,股價處於平穩狀態。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

ADMA Biologics Inc評分

相關信息

行業排名
35 / 157
全市場排名
91 / 4564
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看好

ADMA Biologics Inc亮點

亮點風險
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
業績高增長
公司營業收入穩步增長,連續3年增長97.58%
估值合理
公司最新PE估值12.38,處於3年歷史合理位
機構減倉
最新機構持股218.01M股,環比減少13.44%
活躍度降低
近期活躍度降低,過去20天平均換手率-0.05

分析師目標

基於 5 分析師
買入
評級
17.600
目標均價
+110.27%
漲幅空間

ADMA Biologics Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

ADMA Biologics Inc簡介

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
公司代碼ADMA
公司ADMA Biologics Inc
CEOGrossman (Adam S)
網址https://www.admabiologics.com/

常見問題

ADMA Biologics Inc(ADMA)的當前股價是多少?

ADMA Biologics Inc(ADMA)的當前股價是 8.61。

ADMA Biologics Inc 的股票代碼是什麼?

ADMA Biologics Inc的股票代碼是ADMA。

ADMA Biologics Inc股票的52週最高點是多少?

ADMA Biologics Inc股票的52週最高點是22.37。

ADMA Biologics Inc股票的52週最低點是多少?

ADMA Biologics Inc股票的52週最低點是7.21。

ADMA Biologics Inc的市值是多少?

ADMA Biologics Inc的市值是2.00B。

現在ADMA Biologics Inc(ADMA)的股票是買入、持有還是賣出?

根據分析師評級,ADMA Biologics Inc(ADMA)的總體評級為買入,目標價格為17.60。

ADMA Biologics Inc(ADMA)股票的每股收益(EPS TTM)是多少

ADMA Biologics Inc(ADMA)股票的每股收益(EPS TTM)是0.62。